Información del artículo
El Texto completo está disponible en PDF
Bibliografía
[1.]
S.M. Cotton, M. Lambert, B.G. Schimmelmann, A. Mackinnon, J.F. Gleeson, M. Bork, et al.
Depressive symptoms in first episode schizophrenia spectrum disorder.
Schizophr Res, 134 (2012), pp. 20-26
[2.]
W. An der Heiden, R. Konnecke, K. Maurer, D. Ropeter, H. Hafner.
Depression in the long-term course of schizophrenia.
Eur Arch Psychiatr Clin Neurosci, 255 (2005), pp. 174-184
[3.]
D.A. Morrissette, S.M. Stahl.
Affective symptoms in schizophrenia.
Drug Disc Today Ther Strat, 1–2 (2011), pp. 3-9
[4.]
R. Upthegrove, R. Birchwood, M. Ross, K. Brunett, R. McCollum, L. Jones.
The evolution of depression and suicidality in first episode psychosis.
Acta Psychiatr Scand, 122 (2010), pp. 211-218
[5.]
S.G. Siris, C. Bench.
Depression schizophrenia.
Schizophrenia, 2nd Ed.,
[6.]
S. Majadas, J. José Olivares, J. Galán, T. Díez.
Prevalence of depression and its relationship with other clinical characteristics in a sample of patients with stable schizophrenia.
Compr Psychiatry, 53 (2012), pp. 145-151
[7.]
G. Reine, C. Lançon, S. Di Tucci, C. Sapin, P. Auquier.
Depression and subjective quality of life in chronic phase schizophrenic patients.
Acta Psychiatr Scand, 108 (2003), pp. 297-303
[8.]
C. Lançon, P. Auquier, G. Reine, D. Bernard, D. Addington.
Relationships between depression and psychotic symptoms of schizophrenia during an acute episode and stable period.
Schizophr Res, 47 (2001), pp. 135-140
[9.]
S.J. Bartels, R.E. Drake.
Depressive symptoms in schizophrenia: comprehensive differential diagnosis.
Compr Psychiatry, 29 (1988), pp. 467-483
[10.]
A.R. Yung, L.J. Phillips, H.P. Yuen, S.M. Francey, C.A. McFarlane, M. Hallgren, et al.
Psychosis prediction: 12-month follow up of a high-risk (‘prodromal’) group.
Schizophr Res, 60 (2003), pp. 21-32
[11.]
R. Upthegrove.
Depression in schizophrenia and early psychosis: implications for assessment and treatment.
Adv Psychiatr Treat, 15 (2009), pp. 372-379
[12.]
S.G. Siris.
Depression in schizophrenia: perspectives in the era of “atypical” antipsychotic agents.
Am J Psychiatry, 157 (2000), pp. 1379-1389
[13.]
D. Addington, J. Addington, S. Patten.
Depression in people with first episode schizophrenia.
Br J Psychiatry, 172 (1998), pp. 90-92
[14.]
A. Tapp, N. Kilzieh, A.E. Wood, M. Raskind, R. Tandon.
Depression in patients with schizophrenia during an acute psychotic episode.
Compr Psychiatry, 42 (2001), pp. 314-318
[15.]
A.R. Koreen, S.G. Siris, M. Chakos, J. Alvir, D. Mayerhoff, J. Lieberman.
Depression in first episode psychosis.
Am J Psychiatry, 150 (1993), pp. 1643-1647
[16.]
S.G. Siris, D. Addington, J.M. Azorin, I.R. Falloon, J. Gerlach, S.R. Hirsch.
Depression in schizophrenia: recognition and management in the USA.
Schizophr Res, 47 (2001), pp. 185-197
[17.]
S. Diwan, C.I. Cohen, A.O. Bankole, I. Vahia, M. Kehn, P.M. Ramírez.
Depression in older adults with schizophrenia spectrum disorders: prevalence and associated factors.
Am J Geriatr Psychiatry, 15 (2007), pp. 991-998
[18.]
J.W. Kasckow, S. Zisook.
Co-occurring depressive symptoms in the older patient with schizophrenia.
Drugs Aging, 25 (2008), pp. 631-647
[19.]
C. Mulholland, S. Cooper.
The symptom of depression in schizophrenia and its management.
Adv Psychiatr Treat, 6 (2000), pp. 169-177
[20.]
R.E. Drake, J. Ehrlich.
Suicide attempts associated with akathisia.
Am J Psychiatry, 142 (1985), pp. 499-501
[21.]
J.H. Stephens, C. Astrup, J.C. Mangrum.
Prognostic factors in recovered and deteriorated schizophrenics.
Am J Psychiatry, 122 (1966), pp. 1116-1121
[22.]
D.O. Perkins, H. Gu, P.J. Weiden, J.P. McEvoy, R.M. Hamer, J.A. Lieberman, Comparison of atypicals in first episode study group.
Predictors of treatment discontinuation and medication nonadherence in patients recovering from a first episode of schizophrenia, schizophreniform disorder, or schizoaffective disorder: a randomized, double-blind, flexible-dose, multicenter study.
J Clin Psychiatry, 69 (2008), pp. 106-113
[23.]
K. Hawton, L. Sutton, C. Haw, J. Sinclair, J.J. Deeks.
Schizophrenia and suicide: systematic review of risk factors.
Br J Psychiatry, 187 (2005), pp. 9-20
[24.]
D.A. Johnson.
Depressions in schizophrenia: some observations on prevalence, etiology, and treatment.
Acta Psychiatr Scand Suppl, 291 (1981), pp. 137-144
[25.]
J.R. Sands, M. Harrow.
Depression during the longitudinal course of schizophrenia.
Schizophr Bull, 25 (1999), pp. 157-171
[26.]
R.A. Bressan, A.C. Chaves, L.S. Pilowsky, I. Shirakawa, J.J. Mari.
Depressive episodes in stable schizophrenia: critical evaluation of the DSM-IV and ICD-10 diagnostic criteria.
Psychiatr Res, 117 (2003), pp. 47-56
[27.]
M. Riedel, R. Musil, I. Spellmann, F. Seemüller, H.J. Möller.
Quetiapine XR - A new retard formulation in the treatment of schizophrenia.
Eur Psychiatr Rev, 1 (2008), pp. 70-75
[28.]
C.L. DeVane, C.B. Nemeroff.
Clinical pharmacokinetics of quetiapine: an atypical antipsychotic.
Clin Pharmacokinet, 40 (2001), pp. 509-522
[29.]
C. Figueroa, M. Brecher, J.E. Hamer-Maansson, H. Winter.
Pharmacokinetic profiles of extended release quetiapine fumarate compared with quetiapina immediate release.
Prog Neuropsychopharmacol Biol Psychiatry, 33 (2009), pp. 199-204
[30.]
H.-J. Möller, S. Johnson, T. Mateva, M. Brecher, O. Svensson, F. Miller, et al.
Evaluation of the feasibility of switching from quetiapine immediate release to quetiapine extended release in stable outpatients with schizophrenia.
Int Clin Psychopharmacol, 23 (2008), pp. 95-105
[31.]
J. Peuskens.
The management of schizophrenia: focus on extended-release quetiapine fumarate.
Neuropsychiatr Dis Treat, 7 (2011), pp. 549-564
[32.]
M. Nord, S. Nyberg, J. Brogen, A. Jucaite, C. Halldin, L. Farde.
Comparison of D2 dopamine receptor occupancy after oral administration of quetiapine fumarate immediate-release and extended-release formulations in healthy subjects.
Int J Neuropsychopharmacol, 14 (2011), pp. 1357-1366
[33.]
D.C. Mamo, H. Uchida, I. Vitcu, P. Barsoum, A. Gendron, J. Goldstein, et al.
Quetiapine extended-release versus immediate-release formulation: a positron emission tomography study.
J Clin Psychiatry, 69 (2008), pp. 81-86
[34.]
C. Datto, L. Berggren, J.B. Patel, H. Eriksson.
Self-reported sedation profile of immediate-release quetiapine fumarate compared with extended-release quetiapina fumarate during dose initiation: a randomized, double-blind, crossover study in healthy adult subjects.
Clin Ther, 31 (2009), pp. 492-502
[35.]
H.R. Winter, W.R. Earley, J.E. Hamer-Maanson, P.C. Davis, M.A. Smith.
Steady-state pharmacokinetic, safety, and tolerability profiles of quetiapine, norquetiapine, and other quetiapine metabolites in pediatric and adult patients with psychotic disorders.
J Child Adol Psychopharmacol, 18 (2008), pp. 81-98
[36.]
E. Prieto, J.A. Micó, J.J. Meana, S. Majadas.
Neurobiological bases of quetiapina antidepresant effect in the bipolar disorder.
Actas Esp Psiquiatr, 38 (2010), pp. 22-32
[37.]
M. Sanford, G.M. Keating.
Quetiapine: a review of its use in the management of bipolar depression.
CNS Drugs, 26 (2012), pp. 435-460
[38.]
N.H. Jensen, R.M. Rodriguiz, M.G. Caron, W.C. Wetsel, R.B. Rothman, B.L. Roth.
N-desalkylquetiapine, a potent norepinephrine reuptake inhibitor and partial 5-HT1A agonist, as a putative mediator of quetiapine's antidepressant activity.
Neuropsychopharmacology, 33 (2008), pp. 2303-2312
[39.]
P. Seeman, T. Tallerico.
Rapid release of antipsychotic drugs from dopamine D2receptors: an explanation for low receptor occupancy and early clinical relapse upon wthdrawal of clozapine or quetiapine.
Am J Psychiatry, 156 (1999), pp. 876-884
[40.]
O. Gefvert, T. Lundberg, I.M. Wieselgren, M. Bergström, B. Langstrom, F. Wiesel, et al.
D(2) and 5HT(2A) receptor occupancy of different doses of quetiapina in schizophrenia: a PET study.
Eur Neuropsychopharmacol, 11 (2001), pp. 105-110
[41.]
H.J. Möller.
Antipsychotic and antidepressive effects of second generation antipsychotics. Two different pharmacological mechanisms?.
Eur Arch Psychiatry Clin Neurosci, 255 (2005), pp. 190-201
[42.]
F. Fumagalli, R. Molteni, F. Bedogni, M. Gennarelli, J. Pérez, G. Racagni, et al.
Quetiapine regulates FGF-2 and BDNF expression in the hippocampus of animals treated with MK-801.
NeuroReport, 15 (2004), pp. 2109-2112
[43.]
J. Ichikawa, Z. Li, L. Dai, H.Y. Meltzer.
Atypical antipsychotic drugs, quetiapine, iloperidone, and melperone, preferentially increase dopamine and acetylcholine release in rat medial prefrontal cortex: role of 5-HT1A receptor agonism.
Brain Res, 956 (2002), pp. 349-357
[44.]
S. Nyberg, A. Takano, S. Grimm, B. Gulyas, D. McCarthy, C. Lee, et al.
PET-measured D2, 5-HT2, and norepinephrine transporter (NET) occupancy by quetiapina and N-desalkyl-quetiapine in non-human primates.
Eur Neuropsychopharmacol, 17 (2007), pp. S254-S255
[45.]
H. Xu, Z. Chen, J. He.
Synergetic effects of quetiapine and venlafaxine in preventing the chronic restraint stress-induced decrease in cell proliferation and BDNF expression in rat hippocampus.
Hippocampus, 16 (2006), pp. 551-559
[46.]
J.K. Rybakowski, K. Vansteelandt, T. Szafranski, E. Thys, M. Jarema, W. Wolfgang Fleischhacker, et al.
Treatment of depression in first episode of schizophrenia: Results from EUFEST.
Eur Neuropsychopharmacology, (2012),
[47.]
S. Leucht, W. Kissling, J.M. Davis.
Second-generation antipsychotics for schizophrenia: can we resolve the conflict?.
Psychol Med, 39 (2009), pp. 1591-1602
[48.]
L.A. Arvanitis, B.G. Miller, B.B. Kowalcyk.
Efficacy of ‘Seroquel’ (quetiapine fumerate) in affective symptoms of schizophrenia.
Scientific abstracts of the 36th Annual Meeting of the American College of Neuropsychopharmacology,
[49.]
R.L. Borison, L.A. Arvanitis, B.G. Miller, and the US Seroquel Study Group.
ICI 204,636, an atypical antipsychotic: Efficacy and safety in a multicentre, placebo-controlled trial in patients with schizophrenia.
J Clin Psychopharmacol, 16 (1996), pp. 158-169
[50.]
J.G. Small, S.R. Hirsch, L.A. Arvanitis, B.G. Miller, C.G. Link.
Quetiapine in patients with schizophrenia. A high- and low-dose comparison with placebo.
Arch Gen Psychiatry, 54 (1997), pp. 549-557
[51.]
L.A. Arvanitis, B.G. Miller, and the Seroquel Trial 13 Study Group.
Multiple fixed doses of “Seroquel” (Quetiapine) in patients with acute exacerbation of schizophrenia: A comparison with haloperidol and placebo.
Biol Psychiatry, 42 (1997), pp. 233-246
[52.]
J.M. Goldstein.
Quetiapine fumarate (Seroquel): a new atypical antipsychotic.
Drugs Today (Barc), 35 (1999), pp. 193-210
[53.]
M. Lee, H. Meltzer.
Quetiapine is significantly superior to haloperidol and placebo in improving mood in patients with schizophrenia.
Presented at the 7th Worl Congress of Biological Paychiatry,
[54.]
J. Mullen, M.D. Jibson, D. Sweitzer.
A comparison of the relative safety, efficacy, and tolerability of quetiapine and risperidona in outpatients with schizophrenia and other psychotic disorders: The quetiapine experience with safety and tolerability (QUEST) study.
Clin Ther, 23 (2001), pp. 1839-1854
[55.]
R.A. Emsley, P. Buckley, A.M. Jones, M.R. Greenwood.
Differential effect of quetiapine on depressive symptoms in patients with partially responsive schizophrenia.
J Psychopharmacol, 17 (2003), pp. 210-215
[56.]
S. Kasper.
Quetiapine is effective against anxiety and depressive symptoms in long-term treatment of patients with schizophrenia.
Depress Anxiety, 20 (2004), pp. 44-47
[57.]
E. Kjelby, H.A. Jørgensen, R.A. Kroken, E.M. Løberg, E. Johnsen.
Anti-depressive effectiveness of olanzapine, quetiapine, risperidone and ziprasidone: a pragmatic, randomized trial.
BMC Psychiatry, 31 (2011), pp. 145
[58.]
J.P. McEvoy, P.L. Scheifler, A. Frances.
The Expert Consensus Guidelines Series: treatment of schizophrenia.
J Clin Psychiatry, 60 (1999), pp. 1-80
[59.]
G.S. Alexopoulos, J. Streim, D. Carpenter.
Expert Consensus Panel for Using Antipsychotic Drugs in Older Patients: using antipsychotic agents in older patients.
J Clin Psychiatry, 65 (2004), pp. 5-99
[60.]
R.S. Kahn, S.C. Schulz, V.D. Palazov.
Efficacy and tolerability of once-daily extended release quetiapine fumarate in acute schizophrenia: a randomized, double-blind, placebo-controlled study.
J Clin Psychiatry, 68 (2007), pp. 832-842
[61.]
D. Naber, J. Peuskens, N. Schwarzmann.
Extended-release quetiapine fumarate (quetiapine XR) or risperidone and subjective well-being in schizophrenia.
Presented at the 11th World Congress of Biological Psychiatry,
[62.]
S. Kasper, G. Montagnani, G. Trespi.
Extended release quetiapine fumarate (quetiapine XR) versus risperidone in the treatment of depressive symptoms in schizophrenic or schizoaffective patients.
Presented at the 19th EPA European Congress of Psychiatry,
[63.]
J.M. Tamayo.
Diferencias terapéuticas de los medicamentos para el tratamiento de los trastornos bipolares: siete años después.
Actas Esp Psiquiatr, 39 (2011), pp. 312-330
[64.]
K.R. Merikangas, H.S. Akiskal, J. Angst, P.E. Greenberg, R.M. Hirschfeld, M. Petukhova, et al.
Lifetime and 12-month prevalence of bipolar spectrum disorder in the National Comorbidity Survey replication.
Arch Gen Psychiatry, 64 (2007), pp. 543-552
[65.]
K.N. Fountoulakis, S. Kasper, O. Andreassen.
Efficacy of pharmacotherapy in bipolar disorder: a report by the WPA section on pharmacopsychiatry.
Eur Arch Psychiatry Clin Neurosci, 262 (2012), pp. S1-S48
[66.]
E. Vieta.
Managing bipolar disorder in clinical practice.
Current Medicine Group Ltd, (2007),
[67.]
D.M. Novick, H.A. Swartz, E. Frank.
Suicide attempts in bipolar I and bipolar II disorder: a review and meta-analysis of the evidence.
Bipolar Disord, 12 (2010), pp. 1-9
[68.]
P.G. Janicak, J.T. Rado.
Quetiapine for the treatment of acute bipolar mania, mixed episodes and maintenance therapy.
Expert Opin Pharmacother, 13 (2012), pp. 1645-1652
[69.]
C.L. Bowden, H. Grunze, J. Mullen, M. Brecher, B. Paulsson, M. Jones, et al.
A randomized, double-blind, placebo-controlled efficacy and safety study of quetiapine or lithium as monotherapy for mania in bipolar disorder.
J Clin Psychiatry, 66 (2005), pp. 111-121
[70.]
R.S. McIntyre, M. Brechner, B. Paulsson, K. Huizar, J. Mullen.
Quetiapine or haloperidol as monotherapy for bipolar mania – a 12-week, double-blind, randomised, parallel-group, placebo-controlled trial.
Eur Neuropsychopharmacol, 15 (2005), pp. 573-585
[71.]
E. Vieta, I.F. Nuamah, P. Lim, E.C. Yuen, J.M. Palumbo, D.W. Hough, et al.
A randomized, placebo- and active controlled study of paliperidone extended release for the treatment of acute manic and mixed episodes of bipolar I disorder.
Bipolar Disord, 12 (2010), pp. 230-243
[72.]
S.L. McElroy, B.E. Martens, E.L. Winstanley, R. Creech, S. Malhotra, P.E. Keck.
Placebo-controlled study of quetiapine monotherapy in ambulatory bipolar spectrum disorder with moderate-to-severe hypomania or mild mania.
J Affect Disord, 124 (2010), pp. 157-163
[73.]
H. Li, C. Ma, G. Wang, X. Zhu, M. Peng, N. Gu.
Response and remission rates in Chinese patients with bipolar mania treated for 4 weeks with either quetiapine or lithium: a randomized and double-blind study.
Curr Med Res Opin, 24 (2008), pp. 1-10
[74.]
M.P. DelBello, R.A. Kowatch, C.M. Adler, K.E. Stanford, J.A. Welge, D.H. Barzman, et al.
A double-blind randomized pilot study comparing quetiapine and divalproex for adolescent mania.
J Am Acad Child Adolesc Psychiatry, 45 (2006), pp. 305-313
[75.]
M.P. DelBello, M.L. Schwiers, H.L. Rosenberg, S.M. Strakowski.
A double-blind, randomized, placebo-controlled study of quetiapine as adjunctive treatment for adolescent mania.
J Am Acad Child Adolesc Psychiatry, 41 (2002), pp. 1216-1223
[76.]
G. Sachs, K.N. Chengappa, T. Suppes, J.A. Mullen, M. Brecher, N.A. Devine, et al.
Quetiapine with lithium or divalproex for the treatement of bipolar mania: a randomized, double-blind, placebo-controlled study.
Bipolar Disord, 6 (2004), pp. 213-223
[77.]
L.N. Yatham, B. Paulsson, J. Mullen, A.M. Vagero.
Quetiapine versus placebo in combination with lithium or divalproex for the treatment of bipolar mania.
J Clin Psychopharmacol, 24 (2004), pp. 599-606
[78.]
L.N. Yatham, E. Vieta, A.H. Young, H.J. Möller, B. Paulsson, M. Vagerö.
A double-blind, randomized, placebo-controlled trial of quetiapine as an add-on therapy to lithium or divalproex for the treatment of bipolar mania.
Int Clin Psychopharmacol, 22 (2007), pp. 212-220
[79.]
A.J. Cutler, C. Datto, A. Nordenhem, M. Minkwitz, L. Acevedo, D. Darko.
Extended-release quetiapine as monotherapy for the treatment of adults with acute mania: a randomized, double-blind, 3-week trial.
Clin Ther, 33 (2011), pp. 1643-1658
[80.]
R.K. Al Jurdi, L.A. Dixit, M. Sajatovic.
Role of extended release quetiapine in the management of bipolar disorders.
Neuropsychiatr Dis Treat, 6 (2010), pp. 29-35
[81.]
P.E. Harrison-Read.
Antimanic potency of typical neuroleptic drugs and affinity for dopamine D2 and serotonin 5-HT2A receptors -a new analysis of data from the archives and implications for improved antimanic treatments.
J Psychopharmacol, 23 (2009), pp. 899-907
[82.]
A. Chiesa, F. Chierzi, D. De Ronchi, A. Serretti.
Quetiapine for bipolar depression: a systematic review and meta-analysis.
Int Clin Psychopharmacol, 27 (2012), pp. 76-90
[83.]
J.R. Calabrese, P.E. Keck Jr., W. MacFadden, M. Minkwitz, T.A. Ketter, R.H. Weisler, et al.
A randomized, double-blind, placebo-controlled trial of quetiapina in the treatment of bipolar I or II depression. The BOLDER Study Group.
Am J Psychiatry, 162 (2005), pp. 1351-1360
[84.]
M.E. Thase, W. Macfadden, R.H. Weisler, W. Chang, B. Paulsson, A. Khan, et al.
Efficacy of quetiapine monotherapy in bipolar I and II depression: a double-blind, placebo-controlled study (the BOLDER II study). BOLDER II Study Group.
J Clin Psychopharmacol, 26 (2006), pp. 600-609
[85.]
M.A. Cristancho, M.E. Thase.
The role of quetiapine extended release in the treatment of bipolar depression.
Adv Ther, 27 (2010), pp. 774-784
[86.]
A.H. Young, S.L. McElroy, M. Bauer, N. Phillips, W. Chang, B. Olausson, et al.
A double-blind, placebo-controlled study of quetiapine and lithium monotherapy in adults in the acute phase of bipolar depression (EMBOLDEN I).
J Clin Psychiatry, 71 (2010), pp. 150-162
[87.]
S.L. McElroy, R.H. Weisler, W. Chang, B. Olausson, B. Paulsson, M. Brecher, et al.
A double-blind, placebo-controlled study of quetiapine and paroxetine as monotherapy in adults with bipolar depression (EMBOLDEN II).
J Clin Psychiatry, 71 (2010), pp. 163-174
[88.]
T. Suppes, C. Datto, M. Minkwitz, A. Nordenhem, C. Walker, D. Darko.
Effectiveness of the extended release formulation of quetiapine as monotherapy for the treatment of acute bipolar depression.
J Affect Disord, 121 (2010), pp. 106-115
[89.]
S.A. Montgomery.
The under-recognize role of dopamine in the treatment of major depressive disorder.
Int Clin Psychopharmacol, 23 (2008), pp. 63-69
[90.]
K.R. Connolly, M.E. Thase.
The clinical management of bipolar disorder: A Review of evidence-based guidelines.
Prim Care Companion CNS Disord, 13 (2011),
[91.]
E. Vieta, T. Suppes, I. Eggens, I. Persson, B. Paulsson, M. Brecher.
Efficacy and safety of quetiapine in combination with lithium or divalproex for maintenance of patients with bipolar I disorder (international trial 126).
J Affect Disord, 109 (2008), pp. 251-263
[92.]
T. Suppes, E. Vieta, S. Liu, M. Brecher, B. Paulsson, Trial 127 Investigators.
Maintenance treatment for patients with bipolar I disorder: results from a north american study of quetiapine in combination with lithium or divalproex.
Am J Psychiatry, 166 (2009), pp. 476-488
[93.]
R.H. Weisler, W.A. Nolen, A. Neijber, A. Hellqvist, B. Paulsson, Trial 144 Study Investigators.
Continuation of quetiapine versus switching to placebo or lithium for maintenance treatment of bipolar I disorder.
J Clin Psychiatry, 72 (2011), pp. 1452-1464
[94.]
E. Vieta, O. Gunther, J. Locklear, M. Ekman, C. Miltenburger, M.L. Chatterton, et al.
Effectiveness of psychotropic medications in the maintenance phase of bipolar disorder: a meta-analysis of randomized controlled trials.
Int J Neuropsychopharmacol, 14 (2011), pp. 1029-1049
[95.]
H. Grunze, E. Vieta, G.M. Goodwin, C. Bowden, R.W. Licht, H.J. Möller, et al.
The World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for the biological treatment of bipolar disorders: update 2010 on the treatment of a cute bipolar depression.
World J Biol Psychiatry, 11 (2010), pp. 81-109
[96.]
L.N. Yatham, S.H. Kennedy, A. Schaffer, S.V. Parikh, S. Beaulieu, C. O’Donovan, et al.
Canadian Network for Mood Anxiety Treatments (CNAMAT) and International Society for Bipolar Disorders (ISBD) collaborative update of CANMAT guidelines for the management of patients with bipolar disorder.
Bipolar Disord, 11 (2009), pp. 225-255
[97.]
Grupo de Trabajo de la Guía de Práctica Clínica sobre Trastorno Bipolar. Guía de Práctica Clínica sobre Trastorno Bipolar. Madrid: Plan de Calidad para el Sistema Nacional de Salud del Ministerio de Sanidad, Servicios Sociales e Igualdad. Universidad de Alcalá. Asociación Española de Neuropsiquiatría. 2012. UAH /AEN Núm. 2012.
[98.]
R.C. Kessler, P. Berglund, O. Demler, R. Jin, D. Koretz, K.R. Merikangas, et al.
The epidemiology of major depressive disorder: results from the National Comorbidity Survey Replication (NCS-R).
JAMA, 289 (2003), pp. 3095-3105
[99.]
A. Arauxo, J.M. Cornes, L. Fernández-Ríos.
Prevención de la depresión unipolar en España: realidad y futuro.
Rev Diversitas Perspect Psicol, 4 (2008), pp. 79-92
[100.]
R.C. Kessler, S. Aguilar-Gaxiola, J. Alonso, M.C. Angermeyer, J.C. Anthony, P.A. Berglund, et al.
The WHO World Mental Health (WMH) Surveys.
Psychiatrie, 6 (2009), pp. 5-9
[101.]
G.W. Blair-West, G.W. Mellsop, M.L. Eyeson-Annan.
Down-rating lifetime suicide risk in major depression.
Acta Psychiatr Scand, 95 (1997), pp. 259-263
[102.]
M. Sanford.
Quetiapine extended release adjunctive treatment in major depressive disorder.
CNS Drugs, 25 (2011), pp. 803-813
[103.]
J.R.T. Davidson.
Major depressive disorder treatment guidelines in America and Europe.
J Clin Psychiatry, 71 (2010), pp. e04
[104.]
B. Bortnick, N. El-Khalili, M. Banov, D. Adson, C. Datto, S. Raines, et al.
Efficacy and tolerability of extended release quetiapine fumarate (quetiapine XR) monotherapy in major depressive disorder: A placebo-controlled, randomized study.
J Affect Disord, 128 (2011), pp. 83-94
[105.]
F. López-Muñoz, C. Álamo, P. García-García.
Combination strategies in treatment resistant depression: A focus on selective noradrenaline reuptake inhibitors.
Curr Topics Pharmacol, 13 (2009), pp. 25-50
[106.]
C. Álamo.
Reboxetina en combinación: Una estrategia farmacológica en depresión resistente.
Psiquiatr Día, 8 (2011), pp. 1-9
[107.]
R.C. Shelton, G.I. Papakostas.
Augmentation of antidepressants with atypical antipsychotics for treatment-resistant major depressive disorder.
Acta Psychiatr Scand, 117 (2008), pp. 253-259
[108.]
C. Pae, M.S. Sohi, H. Seo, A. Serretti, A.A. Patkar, D.C. Steffens, X.R. Quetiapine, et al.
Current status for the treatment of major depressive disorder.
Prog Neuro-Psychopharmacol Biol Psychiatr, 34 (2010), pp. 1165-1173
[109.]
A.J. Cutler, S.A. Montgomery, D. Feifel, A. Lazaruz, M. Aström, M. Brecher.
Extended release quetiapina fumarate monotherapy in major depressive disorder: a placebo- and duloxetine-controlled study.
J Clin Psychiatr, 70 (2009), pp. 526-539
[110.]
R. Weisler, M. Joyce, L. McGill, A. Lazarus, J. Szamosi, H. Eriksson, et al.
Extended release quetiapina fumarate monotherapy for major depressive disorder: results of a double-blind, randomized, placebo-controlled study.
CNS Spectr, 14 (2009), pp. 299-313
[111.]
M. Liebowitz, R.W. Lam, U. Lepola, C. Datto, D. Sweitzer, H. Eriksson.
Efficacy and tolerability of extended release quetiapine fumarate monotherapy as maintenance treatment of major depressive disorder: a randomized, placebo-controlled trial.
Depress Anxiety, 27 (2010), pp. 964-976
[112.]
R.H. Weisler, S.A. Montgomery, W.R. Earley.
Efficacy of extended release quetiapine fumarate monotherapy in patients with major depressive disorder: a pooled analysis of two 6-week, double-blind, placebo-controlled studies.
Int Clin Psychopharmacol, 27 (2012), pp. 27-39
[113.]
Atención Primaria de Calidad. Guía de buena práctica clínica en algoritmos de decisión en depresión. Madrid. ISBN: 978-84-695-0702-5. Organización Médica Colegial de España. Ministerio de Sanidad, Política Social e Igualdad. 2011.
[114.]
H. Melander, T. Salmonson, E. Abadie, B. Van Zwieten-Boot.
A regulatory apologia: a review of placebo-controlled studies in regulatory submissions of new-generation antidepressants.
Eur Neuropsychopharmacol, 18 (2008), pp. 623-627
[115.]
A.J. Rush, M.H. Trivedi, S.R. Wisniewski, A.A. Nierenberg, J.W. Stewart, D. Warden, et al.
Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report.
Am J Psychiatry, 163 (2006), pp. 1905-1917
[116.]
M.E. Thase, K. Demyttenaere, W.R. Earley, U. Gustafsson, M. Udd, H. Eriksson.
Extended release quetiapine fumarate in major depressive disorder: analysis in patients with anxious depression.
Depress Anxiety, 29 (2012), pp. 574-586
[117.]
R.A. Hansen, G. Gartlehner, K.N. Lohr, B.N. Gaynes, T.S. Carey.
Efficacy and safety of second-generation antidepressants in the treatment of major depressive disorder.
Ann Intern Med, 143 (2005), pp. 415-426
[118.]
H. Katila, I. Mezhebovsky, A. Mulroy, L. Berggren, H. Eriksson, W. Earley, et al.
Randomized, double-blind study of the efficacy and tolerability of extended release quetiapine fumarate (Quetiapine XR) monotherapy in elderly patients with major depressive disorder.
Am J Geriatr Psychiatry, (2012),
[119.]
M. Bauer, T. Bschor, A. Pfennig, P.C. Whybrow, J. Angst, M. Versiani, et al.
World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of unipolar depressive disorders in primary care.
World J Biol Psychiatry, 8 (2007), pp. 67-104
[120.]
M. Bauer, N. El-Khalili, C. Datto, J. Szamosi, H. Eriksson.
A pooled analysis of two randomised, placebo-controlled studies of extended release quetiapine fumarate adjunctive to antidepressant therapy in patients with major depressive disorder.
J Affect Disord, 127 (2010), pp. 19-30
[121.]
M. Bauer, H.W. Pretorius, E.L. Constant, W.R. Earley, J. Szamosi, M. Brecher.
Extended-release quetiapina as adjunct to an antidepressant in patients with major depressive disorder: results of a randomized, placebo-controlled, double-blind study.
J Clin Psychiatry, 70 (2009), pp. 540-549
[122.]
N. El-Khalili, M. Joyce, S. Atkinson, R.J. Buynak, C. Datto, P. Lindgren, et al.
Extended-release quetiapina fumarate (quetiapine XR) as adjunctive therapy in major depressive disorder (MDD) in patients with an inadequate response to ongoing antidepressant treatment: a multicentre, randomized, double-blind, placebo-controlled study.
Int J Neuropsychopharmacol, 13 (2010), pp. 917-932
[123.]
R.S. McIntyre, D.J. Muzina, A. Adams, M.T. Lourenco, C.W. Law, J.K. Soczynska, et al.
Quetiapine XR efficacy and tolerability as monotherapy and as adjunctive treatment to conventional antidepressants in the acute and maintenance treatment of major depressive disorder: a review of registration trials.
Expert Opin Pharmacother, 10 (2009), pp. 3061-3075
[124.]
P. Blier, N.M. Ward.
Is there a role for 5-HT1A agonists in the treatment of depression?.
Biol Psychiatry, 53 (2003), pp. 193-203
[125.]
O.M. Becker, D.S. Dhanoa, Y. Marantz, D. Chen, S. Shacham, S. Cheruku, et al.
An integrated in silico 3D model-driven discovery of a novel, potent, and selective amidosulfonamide 5-HT1A agonist (PRX-00023) for the treatment of anxiety and depression.
J Med Chem, 49 (2006), pp. 3116-3135
[126.]
L. Pira, R. Mongeau, L. Pani.
The atypical antipsychotic quetiapine increases both noradrenaline and dopamine release in the rat prefrontal cortex.
Eur J Pharmacol, 504 (2004), pp. 61-64
[127.]
J. Ichikawa, H. Ishii, S. Bonaccorso, W.L. Fowler, I.A. O’Laughlin.
Meltzer HY. 5-HT(2A) and D(2) receptor blockade increases cortical DA release via 5-HT(1A) receptor activation: a possible mechanism of atypical antipsychotic-induced cortical dopamine release.
J Neurochem, 76 (2001), pp. 1521-1531
[128.]
L.N. Yatham, J.M. Goldstein, E. Vieta, C.L. Bowden, H. Grunze, R.M. Post, et al.
Atypical antipsychotics in bipolar depression: potentialmechanisms of action.
J Clin Psychiatr, 66 (2005), pp. 40-48
[129.]
F. Tascedda, E. Lovati, J.M. Blom, P. Muzzioli, N. Brunello, G. Racagni, et al.
Regulation of ionotropic glutamate receptors in the rat brain in response to the atypical antipsychotic seroquel (quetiapine fumarate).
Neuropsychopharmacology, 21 (1999), pp. 211-217
Copyright © 2012. Elsevier España, S.L.. Todos los derechos reservados